Brought to you by 
Merck Serono spins out Prexton Therapeutics; provides €2.1mm in seed funding
16 Aug 2012
Executive Summary
In the wake of closing the company’s Geneva headquarters and dealing with resulting restructuring, Merck Serono SA has spun out some of its preclinical Parkinson’s disease assets into a new company, Prexton Therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck Serono spins out Prexton Therapeutics; provides €2.1mm in seed funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice